Harmony Biosciences develops and sells WAKIX for narcolepsy and other treatments for rare neurological diseases. HRMY reports earnings on Wed, Nov 4, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 26 | Wolfe Research | Initiated | Buy | |
| Aug 5 | Truist Securities | Maintained | Hold | |
| Aug 4 | Needham | Maintained | Buy | |
| Jul 31 | Mizuho | Maintained | Buy | |
| Jul 16 | HC Wainwright & Co. | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in HRMY in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HRMY is in one of them and how their past HRMY trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered HRMY in an article yet. Here's the latest on the wider market.
About Harmony Biosciences Holdings
Harmony Biosciences is a neuroscience company based in Plymouth Meeting, Pennsylvania, that focuses on rare neurological diseases. Its main product, WAKIX, is a prescription tablet taken once a day to treat excessive daytime sleepiness and cataplexy in people with narcolepsy. The company is also developing treatments for other rare conditions, including certain epilepsy syndromes. Healthcare providers prescribe its medicines to patients.
- Headquarters
- Plymouth Meeting, PA